Comparison of 3 Different Therapeutic Particles in Radioembolization of Locally Advanced Intrahepatic Cholangiocarcinoma.
Where this comes from
- Record sourced from PubMed, PMID 38176716.
- Also identified by DOI 10.2967/jnumed.123.265597.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Our objective was to compare 3 different therapeutic particles used for radioembolization in locally advanced intrahepatic cholangiocarcinoma. <b>Methods:</b> <sup>90</sup>Y-glass, <sup>90</sup>Y-resin, and <sup>166</sup>Ho-labeled poly(l-lactic acid) microsphere prescribed activity was calculated as per manufacturer recommendations. Posttreatment quantitative <sup>90</sup>Y PET/CT and quantitative <sup>166</sup>Ho SPECT/CT were used to determine tumor-absorbed dose, whole-normal-liver-absorbed dose, treated-normal-liver-absorbed dose, tumor-to-nontumor ratio, lung-absorbed dose, and lung shunt fraction. Response was assessed using RECIST 1.1 and the [<sup>18</sup>F]FDG PET-based change in total lesion glycolysis. Hepatotoxicity was assessed using the radioembolization-induced liver disease classification. <b>Results:</b> Six <sup>90</sup>Y-glass, 8 <sup>90</sup>Y-resin, and 7 <sup>166</sup>Ho microsphere patients were included for analysis. The mean administered activity was 2.6 GBq for <sup>90</sup>Y-glass, 1.5 GBq for <sup>90</sup>Y-resin, and 7.0 GBq for <sup>166</sup>Ho microspheres. Tumor-absorbed dose and treated-normal-liver-absorbed dose were significantly higher for <sup>90</sup>Y-glass than for <sup>90</sup>Y-resin and <sup>166</sup>Ho microspheres (mean tumor-absorbed dose, 197 Gy for <sup>90</sup>Y-glass vs. 73 Gy for <sup>90</sup>Y-resin and 50 Gy for <sup>166</sup>Ho; mean treated-normal-liver-absorbed dose, 79 Gy for <sup>90</sup>Y-glass vs. 37 Gy for <sup>90</sup>Y-resin and 31 Gy for <sup>166</sup>Ho). The whole-normal-liver-absorbed dose and tumor-to-nontumor ratio did not significantly differ between the particles. All patients had a lung-absorbed dose under 30 Gy and a lung shunt fraction under 20%. The 3 groups showed similar toxicity and response according to RECIST 1.1 and [<sup>18</sup>F]FDG PET-based total lesion glycolysis changes. <b>Conclusion:</b> The therapeutic particles used for radioembolization differed from each other and showed significant differences in absorbed dose, whereas toxicity and response were similar for all groups. This finding emphasizes the need for separate dose constraints and dose targets for each particle.
Medical subject headings
- Liver Neoplasms
- Embolization, Therapeutic
- Cholangiocarcinoma
- Bile Duct Neoplasms